AstraZeneca, the maker of the Covishield vaccine, has recently admitted that there are rare side effects of their vaccine, which has led to public unease about its safety and effectiveness. This disclosure brings up the issue of vaccine manufacturers’ openness and the necessity for thorough adverse effects monitoring.
It said, “It is admitted that the AZ vaccine can, in very rare cases, cause TTS. The causal mechanism is not known.” This marks a notable reversal that could lead to a multi-million pound legal payout.
According to the report, the company is being sued in a class action over claims that its vaccine can cause a health issue called Thrombosis with Thrombocytopenia Syndrome (TTS). This condition leads to blood clots forming in the body and a decrease in the number of platelets in the blood. Covishield, developed by AstraZeneca and Oxford University, was widely used during the COVID-19 pandemic, including in India where it was produced by the Serum Institute.
AstraZeneca Side Effects: What is TTS (Thrombosis with Thrombocytopenia Syndrome)?
Thrombosis with Thrombocytopenia Syndrome, or TTS, has recently leapt onto the health scene as a disconcerting condition. This leaflet aims to peel back the layers of this intricate syndrome, providing insights into its root causes, tell-tale symptoms, diagnostics, treatment, and preventative steps.
So, What Exactly is Thrombosis with Thrombocytopenia Syndrome?
In simple terms, TTS is an uncommon yet severe health situation that presents a combo of blood clots and a dip in blood platelet count. Some COVID-19 vaccines, mainly those utilising adenoviral vectors like AstraZeneca and Johnson & Johnson, have been identified in association with this condition. TTS’s enigma lies in its ability to bring forth dire complications such as strokes, heart attacks, and other blood clotting incidents.
“AstraZeneca’s acknowledgment of the link between Covishield and TTS may prompt enhanced safety monitoring and regulatory oversight for vaccines,” experts believe.
